Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 ...

Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Martin Schoen discussing a comparison of outcomes with docetaxel or androgen receptor pathway inhibitor combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

RedHill Biopharma has begun a trial to assess the combination of opaganib and darolutamide for metastatic castrate-resistant ...

Kim Chi presents data from the PSMAfore trial, which compared the hematologic safety of [177Lu]Lu-PSMA-617 to androgen receptor pathway inhibitor (ARPI) changes in taxane-naive mCRPC patients. The ...

with androgen receptor pathway inhibitors (ARPIs; abiraterone, apalutamide, darolutamide, and enzalutamide) and/or docetaxel (DOC). To understand current treatment approaches in clinical practice, we ...

Survey results add to evidence showing that more than half of US patients with mCSPC are still receiving androgen deprivation ... with an androgen receptor pathway inhibitor (ARPI) and/or docetaxel.

in patients who have failed one androgen receptor pathway inhibitor, but have not yet received chemotherapy. Under the terms of the agreement, POINT will complete the study and, if positive ...